Target and Technology
Ladiratuzumab vedotin (SGN-LIV1A) is an antibody-drug conjugate (ADC) that we are developing for the treatment of breast cancer. Most metastatic breast cancers express LIV-1, which also has been detected in a number of other cancers, including melanoma, prostate, ovarian, uterine, and cervical cancers. Ladiratuzumab vedotin consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker. This novel ADC agent is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. Ladiratuzumab vedotin may also cause antitumor activity through other mechanisms, including activation of an immune response.
ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the cell killing power of potent cytotoxic agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.
Clinical Development Status
- Phase 2 I-SPY 2 clinical trial of HER2-negative breast cancer is ongoing
- Two phase 1b/2 clinical trials of ladiratuzumab vedotin in combination with checkpoint inhibitors for breast cancer with a focus on triple negative breast cancer are planned
Proposed Mechanism of Action
SGN-LIV1A is an investigational agent, and its safety and efficacy have not yet been established.